News - evolocumab

Filter

Current filters:

evolocumab

Popular Filters

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

18-12-2013

USA-based biotech company Amgen (Nasdaq: AMGN) has revealed positive top-line Phase III results for its…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Back to top